<h3>享受 TipRanks Premium 50% 折扣，信心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>SinoMab Bioscience Ltd. ( (HK:3681) ) 的最新動態現已發佈。</p>
<p>SinoMab BioScience Limited 宣佈其針對炎症性腸病 (IBD) 的新藥申請 SM17 已獲得中國國家藥品監督管理局的接受。這一進展標誌着 SM17 的應用從特應性皮炎擴展到包括克羅恩病和潰瘍性結腸炎等慢性疾病的重要一步。SM17 獨特的作用機制涉及調節 II 型炎症反應，使其成為應對 IBD 複雜病理的有前景的候選藥物，可能為難治性或複雜疾病表型的患者提供新的治療選擇。公司預計，這一擴展將通過滿足重大的臨牀和商業需求，顯著影響其市場地位。</p>
<p>對 (HK:3681) 股票的最新分析師評級為持有，目標價為 HK$1.50。要查看 SinoMab Bioscience Ltd. 股票的完整分析師預測列表，請訪問 HK:3681 股票預測頁面。</p>
<p><strong>關於 SinoMab Bioscience Ltd. 的更多信息</strong></p>
<p>SinoMab BioScience Limited 是一家專注於新型治療性抗體開發的生物技術公司。該公司在製藥行業運營，主要強調為炎症性疾病（包括特應性皮炎和炎症性腸病）開發治療方案。SinoMab 旨在通過利用其在抗體開發方面的專業知識，解決這些領域中重大的未滿足醫療需求。</p>
<p><strong>平均交易量：</strong> 7,264,409</p>
<p><strong>技術情緒信號：</strong> 賣出</p>
<p><strong>當前市值：</strong> HK$1.95B</p>
<p>要深入瞭解 3681 股票，請訪問 TipRanks 的概述頁面。</p>

<p>SinoMab BioScience Limited 針對 SM17 的新藥臨牀試驗申請已被中國國家藥品監督管理局接受，該藥物針對炎症性腸病。這標誌着 SM17 的應用範圍從特應性皮炎顯著擴展到包括克羅恩病和潰瘍性結腸炎等慢性疾病，可能為複雜的炎症性腸病病例提供一種新穎的治療選擇。公司預計這一發展將通過滿足重大臨牀和商業需求來增強其市場地位</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.</p>
<div class="lb-trans"><p>SinoMab Bioscience Ltd. ( (HK:3681) ) 的最新動態現已發佈。</p>
</div><p>SinoMab BioScience Limited announced that its Investigational New Drug application for SM17, targeting Inflammatory Bowel Disease (IBD), has been accepted by China’s National Medical Products Administration. This development marks a significant step in expanding SM17’s application beyond atopic dermatitis to include chronic conditions like Crohn’s disease and ulcerative colitis. SM17’s unique mechanism of action, which involves modulating Type II inflammatory responses, positions it as a promising candidate for addressing the complex pathology of IBD, potentially offering a novel treatment option for patients with refractory or complex disease phenotypes. The company anticipates that this expansion could significantly impact its market position by addressing substantial clinical and commercial needs.</p>
<div class="lb-trans"><p>SinoMab BioScience Limited 宣佈其針對炎症性腸病 (IBD) 的新藥申請 SM17 已獲得中國國家藥品監督管理局的接受。這一進展標誌着 SM17 的應用從特應性皮炎擴展到包括克羅恩病和潰瘍性結腸炎等慢性疾病的重要一步。SM17 獨特的作用機制涉及調節 II 型炎症反應，使其成為應對 IBD 複雜病理的有前景的候選藥物，可能為難治性或複雜疾病表型的患者提供新的治療選擇。公司預計，這一擴展將通過滿足重大的臨牀和商業需求，顯著影響其市場地位。</p>
</div><p>The most recent analyst rating on (HK:3681) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.</p>
<div class="lb-trans"><p>對 (HK:3681) 股票的最新分析師評級為持有，目標價為 HK$1.50。要查看 SinoMab Bioscience Ltd. 股票的完整分析師預測列表，請訪問 HK:3681 股票預測頁面。</p>
</div><p><strong>More about SinoMab Bioscience Ltd.</strong></p>
<div class="lb-trans"><p><strong>關於 SinoMab Bioscience Ltd. 的更多信息</strong></p>
</div><p>SinoMab BioScience Limited is a biotechnology company focused on the development of novel therapeutic antibodies. The company operates in the pharmaceutical industry, with a primary emphasis on creating treatments for inflammatory diseases, including atopic dermatitis and inflammatory bowel disease. SinoMab aims to address significant unmet medical needs in these areas by leveraging its expertise in antibody development.</p>
<div class="lb-trans"><p>SinoMab BioScience Limited 是一家專注於新型治療性抗體開發的生物技術公司。該公司在製藥行業運營，主要強調為炎症性疾病（包括特應性皮炎和炎症性腸病）開發治療方案。SinoMab 旨在通過利用其在抗體開發方面的專業知識，解決這些領域中重大的未滿足醫療需求。</p>
</div><p><strong>Average Trading Volume:</strong> 7,264,409</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 7,264,409</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技術情緒信號：</strong> 賣出</p>
</div><p><strong>Current Market Cap:</strong> HK$1.95B</p>
<div class="lb-trans"><p><strong>當前市值：</strong> HK$1.95B</p>
</div><p>For an in-depth examination of 3681 stock, go to TipRanks’ Overview page.</p>
<div class="lb-trans"><p>要深入瞭解 3681 股票，請訪問 TipRanks 的概述頁面。</p>
</div>

SinoMab 公司用於治療 IBD 的 SM17 新藥臨牀試驗申請已獲 NMPA 受理